Biocon also aims to file for an initial public offering (IPO) within the next two years that could value the company at more than $10 billion. Biocon's executive chair Kiran Mazumdar-Shaw said the ...

Biocon and Mylan managed to get their Herceptin biosimilar approved by the FDA last month. Sandoz is also a major player in this field and was the first company to get a biosimilar approved in ...

Seamless reading experience. Save your favourite. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon ...

Biocon Ltd divested a 2% stake in Syngene International, generating Rs 686 crore through an open market transaction. Kiran Mazumdar Shaw's Biocon sold 80 lakh shares at Rs 857.68 each. The promoter ...

Biocon Group's generics business continues to ... Peter Bains, Group CEO, tells FE in an interview that the company’s long-term debt restructuring through a combination of $800 million dollar ...

Biocon said, in its latest earnings concall, that it entered into definitive agreements with KSSF for structured funding. This, the company added, would help reduce its net debt. “Viatris ...

Biocon is part of Syngene's promoter group and owned a 54.45 percent stake in the CDMO company as per its latest shareholding data. Shares of Syngene International reeled under selling pressure ...